Generic Name and Formulations:
Ropivacaine HCl 2mg/mL, 5mg/mL, 7.5mg/mL, 10mg/mL; soln for epidural inj; preservative-free.
Fresenius Kabi USA
Indications for NAROPIN:
For the production of local or regional anesthesia for surgery (epidural block including cesarean section, major nerve block, local infiltration) and for acute pain management (epidural continuous infusion or intermittent bolus, eg, postop or labor; local infiltration).
See literature. Avoid intravascular or rapid inj of large volumes. Use test dose (3–5mL of short acting local anesthetic soln containing epinephrine) prior to induction of complete block. Individualize. A cumulative dose of up to 770mg administered over 24 hours is well tolerated in adults with post-op pain management. Debilitated: caution with prolonged periods of administration (eg, >70hrs).
Should only be administered by trained medical professionals; have resuscitative equipment available. Unintended IV inj may result in cardiac arrest (esp. in elderly and patients with concomitant heart disease); prolonged resuscitative efforts may be required. Not for emergency situations. Have protocol for malignant hyperthermia management available. Impaired cardiovascular function. Hypotension. Hypovolemia. Heart block. Hepatic disease. Renal impairment. Labor & delivery; monitor fetal heart rate. Pregnancy (Cat.B). Nursing mothers.
Local anesthetic (amide-type).
Additive toxic effects with other local anesthetics. Additive cardiac effects possible with concomitant Class III antiarrhythmics (eg, amiodarone); consider ECG monitoring. May be potentiated by CYP1A2 inhibitors (eg, fluvoxamine, theophylline, imipramine) and potent CYP3A4 inhibitors (eg, ketoconazole).
Hypotension, GI upset, bradycardia, fever, pain, postop complications, anemia, paresthesia, headache, pruritus, back pain.
Polyamp DuoFit Sterile Pak—5; Single-dose vials (5mg/mL)—1, 5; Single-dose infusion bottles (2mg/mL)—1 (100mL, 200mL)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC